NCT05752773 (MI-PPGL) is a clinical trial in PGL, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT05752773?

NCT05752773 is sponsored by Peking Union Medical College Hospital.

Is NCT05752773 still recruiting?

NCT05752773 is currently status unknown. Last updated 8 March 2023.

Last reviewed 2023-03-08 · How we verify

NCT05752773: MI-PPGL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma Resection

Status unknown Last updated 8 March 2023

What this trial tests

trial in PGL in 700 participants. Status unknown.

Timeline

6 February 2023

Primary endpoint
31 May 2025

31 May 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	700
Start date	6 February 2023
Primary completion	31 May 2025
Estimated completion	31 May 2025
Sites	1 location across China

Conditions studied

PGL — all drugs for PGL →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 85, any sex, with PGL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study was conducted in patients undergoing elective laparoscopic pheochromocytoma/paraganglioma(PPGL) resection. It mainly answers the following two main questions: 1. What are the risk factors for myocardial injury after laparoscopic PPGL resection？ 2. How to establish the myocardial injury prediction model of laparoscopic PPGL resection? Participants were not required to perform additional research work other than the usual postoperative follow-up within 30 days after surgery. No control group was set in this study, and no additional clinical intervention was performed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prediction of postoperative myocardial injury in patients undergoing laparoscopic pheochromocytoma/paraganglioma resection: protocol for an ambispective cohort study.
Lan L, Ma Y, Zhao Y, Li Y, et al · · 2025 · PMID 39920072 · DOI 10.1136/bmjopen-2024-091975

Verify or expand the search:

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05752773 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 8 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05752773.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing